Start for free
Start for free
Nantahala Capital Management logo

Nantahala Capital Management

North America, Connecticut, United States, New Canaan

Description

Nantahala Capital Management is a hedge fund.

Investor Profile

Nantahala Capital Management has made 41 investments, with 13 in the past 12 months and 20% as lead.

Stage Focus

  • Post Ipo Equity (95%)
  • Series C (2%)
  • Series Unknown (2%)

Country Focus

  • United States (80%)
  • Israel (7%)
  • Canada (5%)
  • Germany (2%)
  • Sweden (2%)
  • Norway (2%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
  • Medical Device
  • Health Diagnostics
  • Biopharma
  • Manufacturing
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Nantahala Capital Management frequently co-invest with?

EcoR1 Capital
EcoR1 Capital
North America, California, United States, San Francisco
Co-Investments: 4
OrbiMed
OrbiMed
North America, New York, United States, New York
Co-Investments: 4
Samsara BioCapital
Samsara BioCapital
North America, California, United States, Palo Alto
Co-Investments: 5
Adage Capital Management
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Frazier Life Sciences
Frazier Life Sciences
North America, California, United States, Menlo Park
Co-Investments: 4
RA Capital Management
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 4
Perceptive Advisors
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 8
VC
Velan Capital
North America, Georgia, United States, Alpharetta
Co-Investments: 5
Armistice Capital
Armistice Capital
North America, New York, United States, New York
Co-Investments: 4
SC
Stonepine Capital Management
North America, Oregon, United States, Bend
Co-Investments: 7

What are some of recent deals done by Nantahala Capital Management?

Opus Genetics(formerly Ocuphire Pharma)

Farmington Hills, Michigan, United States

Ocuphire Pharma, a clinical-stage biopharmaceutical company, develops and commercializes therapies for patients with ophthalmic disorders.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityMar 21, 2025
Amount Raised: $20,000,000
BIOMx

Ness Ziona, HaMerkaz, Israel

BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.

BiotechnologyHealth CareTherapeutics
Post Ipo EquityFeb 26, 2025
Amount Raised: $12,000,000
Edesa Biotech

Markham, Ontario, Canada

Edesa develops treatments for dermatological and anorectal diseases. Edesa merged with Stellar Biotechnologies in 2019.

BiotechnologyLife Science
Post Ipo EquityFeb 13, 2025
Amount Raised: $10,509,103
Grace Therapeutics

Laval, Quebec, Canada

Grace Therapeutics is an emerging biopharmaceutical company.

BiotechnologyHealth CareMedicalPharmaceuticalTherapeutics
Post Ipo EquityFeb 10, 2025
Amount Raised: $10,467,142
Palvella Therapeutics

Wayne, Pennsylvania, United States

Palvella Therapeutics focuses on relentlessly and selflessly serving abandoned patient populations with therapies.

BiotechnologyHealth CareLife ScienceTherapeutics
Post Ipo EquityDec 13, 2024
Senti Biosciences

South San Francisco, California, United States

Senti Biosciences is a biotechnology company that focuses on synthetic biology and gene circuit engineering for therapeutic applications.

BiotechnologyHealth CareMedicalTherapeutics
Post Ipo EquityDec 2, 2024
Amount Raised: $47,600,000
Apyx Medical

Clearwater, Florida, United States

Apyx Medical manufactures digital electrosurgical generators and accessories for the operating room and surgicenter.

Health CareManufacturingMedical Device
Post Ipo EquityNov 8, 2024
Amount Raised: $7,000,000
Eledon Pharmaceuticals

Irvine, California, United States

Eledon Pharmaceuticals is a biotechnology company developing treatments for people undergoing organ or cellular transplantation.

BiotechnologyHealth CareMedicalPharmaceutical
Post Ipo EquityOct 29, 2024
Amount Raised: $85,000,000
Inhibikase Therapeutics

Atlanta, Georgia, United States

Inhibikase Therapeutics is a developer of cellular Abelson tyrosine kinase inhibitors to treat infections and other diseases.

Health CareHealth DiagnosticsTherapeutics
Post Ipo EquityOct 9, 2024
Amount Raised: $110,000,000
Savara Pharmaceuticals

Austin, Texas, United States

Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.

BiopharmaBiotechnologyPharmaceutical
Post Ipo EquityJun 28, 2024
Amount Raised: $100,000,000
c-shape-1
c-shape-2

Ready to Raise Capital?

Founders in our network have raised from Y Combinator, Sequoia, a16z, and more. You could be next.

Find investors

Pages

Find investorsPricing

Free tools

Pre-Money and Post-Money Valuation Calculator